{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:22:13Z","timestamp":1761567733958,"version":"build-2065373602"},"reference-count":128,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,2,4]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n                    Cystic fibrosis (CF) is a genetic disorder with involvement of many organ systems. For some of the affected organs, the dysfunction is a direct consequence of cystic fibrosis transmembrane conductance regulator (CFTR) deficiency, while in others the pathophysiology is complex and may be influenced by treatments and social factors. Recent decades have seen improved wellbeing and survival of people with CF, even more so with the introduction of CFTR modulator treatments. For many manifestations of CF, the focus has shifted from treatment of complications to screening and monitoring for early detection of complications, and prevention of treatment-related complications. Examples are early detection of\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    airway infection and CF-related diabetes, and more-recently adopted strategies such as screening for colorectal cancer and anxiety and depression. In this article we review well-documented and emerging CF manifestations, risk factors for complications, and strategies recommended by international society guidelines and care recommendations for prevention, screening and monitoring. We review existing guideline-based recommendations with a glimpse at emerging modalities for screening and monitoring which may be adopted in the future. Finally, we review the changes due to treatment with CFTR modulators and their possible implications for future screening and monitoring strategies. As people with CF enjoy better quality of life and improved survival, screening for CF-related morbidities will be evolving constantly.\n                  <\/jats:p>","DOI":"10.1183\/23120541.01235-2024","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T12:00:26Z","timestamp":1739448026000},"page":"01235-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening and monitoring across the lifespan of an ageing cystic fibrosis population"],"prefix":"10.1183","volume":"11","author":[{"given":"Karin","family":"Yaacoby-Bianu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raya","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-3398","authenticated-orcid":false,"given":"Michal","family":"Shteinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2025102704051883000_11.5.01235-2024.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32542-3"},{"key":"2025102704051883000_11.5.01235-2024.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01609-4"},{"key":"2025102704051883000_11.5.01235-2024.3","unstructured":"Zolin A , Orenti A , Jung A , et al. ECFSPR Annual Report 2021. 2023. https:\/\/www.ecfs.eu\/sites\/default\/files\/Annual%20Report_2021_09Jun2023_ECFSPR_final.pdf"},{"key":"2025102704051883000_11.5.01235-2024.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.02.006"},{"key":"2025102704051883000_11.5.01235-2024.5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcf.2024.05.007","article-title":"Standards for the care of people with cystic fibrosis (CF); planning for a longer life","volume":"23","author":"Gramegna","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.1_suppl.1S"},{"key":"2025102704051883000_11.5.01235-2024.7","unstructured":"Cystic Fibrosis Trust . Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK. 2nd Edn. 2011. https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2022-10\/Standards%20of%20care_interim%202022.pdf"},{"key":"2025102704051883000_11.5.01235-2024.8","unstructured":"Douglas T , Mulrennan S . Standards of Care for Cystic Fibrosis. 2023. https:\/\/www.cysticfibrosis.org.au\/wp-content\/uploads\/2023\/08\/CFA_Standard-of-Care_Design_Refresh_2023.16.08.23-TD-EDITS.pdf"},{"key":"2025102704051883000_11.5.01235-2024.9","unstructured":"National Institute for Health and Care Excellence (NICE) . Cystic Fibrosis: Diagnosis and Management. 2017. https:\/\/www.nice.org.uk\/guidance\/ng78"},{"key":"2025102704051883000_11.5.01235-2024.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.01.007"},{"key":"2025102704051883000_11.5.01235-2024.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311003"},{"key":"2025102704051883000_11.5.01235-2024.12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jcf.2023.11.001","article-title":"Monitoring of ECFS quality standards for the clinical management of adults with cystic fibrosis","volume":"23","author":"Gramegna","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.13","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ppul.25371","article-title":"How abnormal is the normal? Clinical characteristics of CF patients with normal","volume":"56","author":"Cohen-Cymberknoh","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2025102704051883000_11.5.01235-2024.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201310-1747OC"},{"key":"2025102704051883000_11.5.01235-2024.15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1164\/rccm.201604-0893OC","article-title":"Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis","volume":"195","author":"Stahl","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025102704051883000_11.5.01235-2024.16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/03007995.2016.1268999","article-title":"Developments in multiple breath washout testing in children with cystic fibrosis","volume":"33","author":"Saunders","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2025102704051883000_11.5.01235-2024.17","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.3390\/jcm12144735","article-title":"Pulmonary function tests in the evaluation of early lung disease in cystic fibrosis","volume":"12","author":"Walicka-Serzysko","year":"2023","journal-title":"J Clin Med"},{"key":"2025102704051883000_11.5.01235-2024.18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00247-022-05522-4","article-title":"Chest radiography and computed tomography imaging in cystic fibrosis: current challenges and new perspectives","volume":"53","author":"Ciet","year":"2023","journal-title":"Pediatr Radiol"},{"key":"2025102704051883000_11.5.01235-2024.19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older \u2013 the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2025102704051883000_11.5.01235-2024.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0219OC"},{"key":"2025102704051883000_11.5.01235-2024.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00004-2024"},{"key":"2025102704051883000_11.5.01235-2024.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)82653-8"},{"key":"2025102704051883000_11.5.01235-2024.23","unstructured":"Cystic Fibrosis Foundation . Patient Registry Annual Data Report. 2024. https:\/\/www.cff.org\/media\/31216\/download\/"},{"key":"2025102704051883000_11.5.01235-2024.24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(18)30171-1","article-title":"The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial","volume":"6","author":"Ronchetti","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025102704051883000_11.5.01235-2024.25","first-page":"CD009530","article-title":"Bronchoscopy-guided antimicrobial therapy for cystic fibrosis","volume":"5","author":"Jain","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2025102704051883000_11.5.01235-2024.26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.27","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1696726"},{"key":"2025102704051883000_11.5.01235-2024.28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jcf.2023.02.008","article-title":"Early life growth trajectories in cystic fibrosis are associated with lung function at age six","volume":"22","author":"Psoter","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.29","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcf.2021.12.014","article-title":"Nutritional status and lung function in children with pancreatic-sufficient cystic fibrosis","volume":"21","author":"Madde","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.03.004"},{"key":"2025102704051883000_11.5.01235-2024.31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin Nutr"},{"key":"2025102704051883000_11.5.01235-2024.32","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jcf.2017.07.010","article-title":"Nutrition: prevention and management of nutritional failure in cystic fibrosis","volume":"16","author":"Sullivan","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.33","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/nu14061216","article-title":"The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity","volume":"14","author":"Bailey","year":"2022","journal-title":"Nutrients"},{"key":"2025102704051883000_11.5.01235-2024.34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US Cystic Fibrosis Foundation Patient Registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.35","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.36","first-page":"100290","article-title":"Cystic fibrosis-related diabetes: prevalence, screening, and diagnosis","volume":"27","author":"Khare","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"2025102704051883000_11.5.01235-2024.37","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0586"},{"key":"2025102704051883000_11.5.01235-2024.38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.10.009","article-title":"Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome; Olesen et al","volume":"19","author":"Olesen","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.39","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1576"},{"key":"2025102704051883000_11.5.01235-2024.40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jcf.2021.04.014","article-title":"Cystic fibrosis-related diabetes (CFRD) and cognitive function in adults with cystic fibrosis","volume":"21","author":"Chadwick","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.41","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2019.07.010","article-title":"The association of pediatric cystic fibrosis-related diabetes screening on clinical outcomes by center: a CF patient registry study","volume":"19","author":"Franck Thompson","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.42","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1768"},{"key":"2025102704051883000_11.5.01235-2024.43","first-page":"100298","article-title":"Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: a French survey from the 47 centers","volume":"28","author":"Weiss","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2025102704051883000_11.5.01235-2024.44","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2025102704051883000_11.5.01235-2024.45","doi-asserted-by":"crossref","first-page":"102899","DOI":"10.1016\/j.dsx.2023.102899","article-title":"Advances in cystic fibrosis-related diabetes: current status and future directions","volume":"17","author":"Lurquin","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"2025102704051883000_11.5.01235-2024.46","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jcf.2017.07.002","article-title":"Cystic fibrosis-related cirrhosis","volume":"16","author":"Leung","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.47","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2016.03.041","article-title":"Features of severe liver disease with portal hypertension in patients with cystic fibrosis","volume":"14","author":"Stonebraker","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102704051883000_11.5.01235-2024.48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.29217","article-title":"Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity","volume":"66","author":"Koh","year":"2017","journal-title":"Hepatology"},{"key":"2025102704051883000_11.5.01235-2024.49","unstructured":"Vertex Pharmaceuticals . SYMDEKO Prescribing Information: SYMDEKOTM (Tezacaftor\/Ivacaftor) Tablets; (Ivacaftor) Tablets, for Oral Use. Initial U.S. Approval: 2018. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210491lbl.pdf"},{"key":"2025102704051883000_11.5.01235-2024.50","unstructured":"Vertex Pharmaceuticals . ORKAMBI Prescribing Information: ORKAMBI\u00ae (Lumacaftor\/Ivacaftor) Tablets, for Oral Use. ORKAMBI\u00ae (Lumacaftor\/Ivacaftor) Oral Granules. Initial U.S. Approval: 2015. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211358s000lbl.pdf"},{"key":"2025102704051883000_11.5.01235-2024.51","unstructured":"Vertex Pharmaceuticals . TRIKAFTA Prescribing Information: TRIKAFTATM (Elexacaftor, Tezacaftor and Ivacaftor Tablets; Ivacaftor Tablets), Co-packaged for Oral Use. Initial U.S. Approval: 2019. 2019. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212273s000lbl.pdf"},{"key":"2025102704051883000_11.5.01235-2024.52","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-023-01969-3","article-title":"Aetiology of significant liver test abnormalities in a single-centre cohort of people with cystic fibrosis exposed to elexacaftor\/tezacaftor\/ivacaftor, utilizing the updated RUCAM","volume":"83","author":"Tewkesbury","year":"2023","journal-title":"Drugs"},{"key":"2025102704051883000_11.5.01235-2024.53","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.japh.2023.02.015","article-title":"Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor","volume":"63","author":"Wood","year":"2023","journal-title":"J Am Pharm Assoc"},{"key":"2025102704051883000_11.5.01235-2024.54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","volume":"22","author":"Tewkesbury","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.55","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcf.2023.09.006","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor on liver fibrosis markers in adults with cystic fibrosis","volume":"23","author":"Tewkesbury","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcf.2021.07.018","article-title":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","volume":"21","author":"Drummond","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clinthera.2023.11.003","article-title":"Stepwise introduction of elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and liver cirrhosis Child\u2013Pugh A or B using clinical and therapeutic drug monitoring: a case series","volume":"46","author":"Vonk","year":"2024","journal-title":"Clin Ther"},{"key":"2025102704051883000_11.5.01235-2024.58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ppul.25779","article-title":"The use of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis postliver transplant: a case series","volume":"57","author":"Ragan","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"2025102704051883000_11.5.01235-2024.59","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","article-title":"Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations","volume":"79","author":"Sellers","year":"2024","journal-title":"Hepatology"},{"key":"2025102704051883000_11.5.01235-2024.60","doi-asserted-by":"crossref","first-page":"e0178784","DOI":"10.1371\/journal.pone.0178784","article-title":"Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: results from a prospective longitudinal cohort study","volume":"12","author":"Klotter","year":"2017","journal-title":"PLoS One"},{"key":"2025102704051883000_11.5.01235-2024.61","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1148\/radiographics.20.3.g00ma08767","article-title":"Hepatobiliary and pancreatic manifestations of cystic fibrosis: MR imaging appearances","volume":"20","author":"King","year":"2000","journal-title":"Radiographics"},{"key":"2025102704051883000_11.5.01235-2024.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502233320803"},{"key":"2025102704051883000_11.5.01235-2024.63","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs481"},{"key":"2025102704051883000_11.5.01235-2024.64","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30188-8"},{"key":"2025102704051883000_11.5.01235-2024.65","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/ijc.33431","article-title":"Cystic fibrosis F508del carriers and cancer risk: results from the UK Biobank","volume":"148","author":"Shi","year":"2021","journal-title":"Int J Cancer"},{"key":"2025102704051883000_11.5.01235-2024.66","doi-asserted-by":"publisher","DOI":"10.1097\/mcg.0000000000000034"},{"key":"2025102704051883000_11.5.01235-2024.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2016.01.002"},{"key":"2025102704051883000_11.5.01235-2024.68","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2017.10.036","article-title":"Cost effectiveness of screening individuals with cystic fibrosis for colorectal cancer","volume":"154","author":"Gini","year":"2018","journal-title":"Gastroenterology"},{"key":"2025102704051883000_11.5.01235-2024.69","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.12.012"},{"key":"2025102704051883000_11.5.01235-2024.70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12876-019-0979-z","article-title":"A non-randomised single centre cohort study, comparing standard and modified bowel preparations, in adults with cystic fibrosis requiring colonoscopy","volume":"19","author":"Matson","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"2025102704051883000_11.5.01235-2024.71","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-009-9316-9"},{"key":"2025102704051883000_11.5.01235-2024.72","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/MCP.0000000000000624","article-title":"Prevention of osteoporosis in cystic fibrosis","volume":"25","author":"Chedevergne","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2025102704051883000_11.5.01235-2024.73","doi-asserted-by":"crossref","first-page":"e48947","DOI":"10.2196\/48947","article-title":"Sex- and age-specific prevalence of osteopenia and osteoporosis: sampling survey","volume":"10","author":"Fan","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"2025102704051883000_11.5.01235-2024.74","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","article-title":"European cystic fibrosis bone mineralisation guidelines","volume":"10","author":"Sermet-Gaudelus","year":"2011","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.75","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jcf.2022.01.011","article-title":"Bone mineral density screening by DXA for people with cystic fibrosis: a registry analysis of patient and program factors influencing rates of screening","volume":"21","author":"Ratti","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.76","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205983"},{"key":"2025102704051883000_11.5.01235-2024.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106147"},{"key":"2025102704051883000_11.5.01235-2024.78","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ccm.2022.06.014","article-title":"Management of mental health in cystic fibrosis","volume":"43","author":"Bathgate","year":"2022","journal-title":"Clin Chest Med"},{"key":"2025102704051883000_11.5.01235-2024.79","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207488"},{"key":"2025102704051883000_11.5.01235-2024.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.02.005"},{"key":"2025102704051883000_11.5.01235-2024.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.10.043"},{"key":"2025102704051883000_11.5.01235-2024.82","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.83","doi-asserted-by":"crossref","first-page":"1156621","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: a case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025102704051883000_11.5.01235-2024.84","doi-asserted-by":"crossref","first-page":"1179208","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025102704051883000_11.5.01235-2024.85","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202404-0787LE"},{"key":"2025102704051883000_11.5.01235-2024.86","first-page":"F1038","article-title":"Both the wild type and a functional isoform of CFTR are expressed in kidney","volume":"270","author":"Morales","year":"1996","journal-title":"Am J Physiol"},{"key":"2025102704051883000_11.5.01235-2024.87","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1681\/ASN.0000000000000173","article-title":"Loss of the secretin receptor impairs renal bicarbonate excretion and aggravates metabolic alkalosis in mice during acute base-loading","volume":"34","author":"Berg","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025102704051883000_11.5.01235-2024.88","doi-asserted-by":"crossref","unstructured":"Shteinberg M , Stahl M . Other cystic fibrosis-related diseases and complications. In: Bush A , Amaral MD , Davies JC , et al. Hodson and Geddes\u2019 Cystic Fibrosis. Boca Raton, CRC Press, 2023; pp. 389\u2013405.","DOI":"10.1201\/9781003262763-38"},{"key":"2025102704051883000_11.5.01235-2024.89","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)69068-2"},{"key":"2025102704051883000_11.5.01235-2024.90","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/13506129.2014.943834","article-title":"Cystic fibrosis and AA amyloidosis: a survey in the French cystic fibrosis network","volume":"21","author":"Stankovic Stojanovic","year":"2014","journal-title":"Amyloid"},{"key":"2025102704051883000_11.5.01235-2024.91","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sft146"},{"key":"2025102704051883000_11.5.01235-2024.92","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20138"},{"key":"2025102704051883000_11.5.01235-2024.93","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.087098"},{"key":"2025102704051883000_11.5.01235-2024.94","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12967-019-02139-4","article-title":"Renal involvement and metabolic alterations in adults patients affected by cystic fibrosis","volume":"17","author":"Lai","year":"2019","journal-title":"J Transl Med"},{"key":"2025102704051883000_11.5.01235-2024.95","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0932OC"},{"key":"2025102704051883000_11.5.01235-2024.96","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/adc.78.6.540","article-title":"Urinary N-acetyl-\u03b2 -d-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation","volume":"78","author":"Ring","year":"1998","journal-title":"Arch Dis Child"},{"key":"2025102704051883000_11.5.01235-2024.97","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10185"},{"key":"2025102704051883000_11.5.01235-2024.98","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/antibiotics10040424","article-title":"Unknown renal impairment: a rare case of inhaled tobramycin induced acute kidney injury in a cystic fibrosis patient","volume":"10","author":"Miller","year":"2021","journal-title":"Antibiotics"},{"key":"2025102704051883000_11.5.01235-2024.99","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2022.08.010","article-title":"Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection \u2013 a European Cystic Fibrosis Patient Registry data analysis","volume":"22","author":"Orenti","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.100","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02980"},{"key":"2025102704051883000_11.5.01235-2024.101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17906-9"},{"key":"2025102704051883000_11.5.01235-2024.102","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202102-0461OC"},{"key":"2025102704051883000_11.5.01235-2024.103","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jcf.2022.04.006","article-title":"Antipseudomonal treatment decisions during CF exacerbation management","volume":"21","author":"VanDevanter","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.104","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jcf.2021.11.013","article-title":"Acute ST-elevation myocardial infarction in two young women with cystic fibrosis and cystic fibrosis-related diabetes","volume":"21","author":"Thambuluru","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.105","first-page":"233","article-title":"A devastating cardiovascular event in an adult cystic fibrosis patient: an unforeseen outcome of increasing life expectancy","volume":"25","author":"Hussain","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"2025102704051883000_11.5.01235-2024.106","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2021.11.008","article-title":"Forewarned is forearmed: the cardiovascular time bomb in cystic fibrosis","volume":"21","author":"Duckers","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.107","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.healun.2010.08.024","article-title":"Impact of lung transplantation on serum lipids in adults with cystic fibrosis","volume":"30","author":"Nash","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"2025102704051883000_11.5.01235-2024.108","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jcf.2023.10.002","article-title":"Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis","volume":"22","author":"Despotes","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.04.016"},{"key":"2025102704051883000_11.5.01235-2024.110","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22974"},{"key":"2025102704051883000_11.5.01235-2024.111","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"key":"2025102704051883000_11.5.01235-2024.112","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2024.01.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor improves chronic rhinosinusitis detected by magnetic resonance imaging in children with cystic fibrosis on long-term therapy with lumacaftor\/ivacaftor","volume":"23","author":"Wucherpfennig","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.113","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1044\/2021_AJA-21-00031","article-title":"Clinical considerations for routine auditory and vestibular monitoring in patients with cystic fibrosis","volume":"30","author":"Garinis","year":"2021","journal-title":"Am J Audiol"},{"key":"2025102704051883000_11.5.01235-2024.114","doi-asserted-by":"publisher","DOI":"10.1080\/00016480801968534"},{"key":"2025102704051883000_11.5.01235-2024.115","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.9.2502-2509.2001"},{"key":"2025102704051883000_11.5.01235-2024.116","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23763"},{"key":"2025102704051883000_11.5.01235-2024.117","doi-asserted-by":"publisher","DOI":"10.1038\/ng0793-289"},{"key":"2025102704051883000_11.5.01235-2024.118","doi-asserted-by":"publisher","DOI":"10.1177\/0194599813482705"},{"key":"2025102704051883000_11.5.01235-2024.119","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318156dd07"},{"key":"2025102704051883000_11.5.01235-2024.120","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.131532"},{"key":"2025102704051883000_11.5.01235-2024.121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc053428"},{"key":"2025102704051883000_11.5.01235-2024.122","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002295"},{"key":"2025102704051883000_11.5.01235-2024.123","doi-asserted-by":"crossref","first-page":"110808","DOI":"10.1016\/j.ijporl.2021.110808","article-title":"Effects of long-term azithromycin therapy on auditory functions in children with chronic respiratory diseases","volume":"147","author":"Yazan","year":"2021","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2025102704051883000_11.5.01235-2024.124","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcf.2021.08.035","article-title":"Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network","volume":"20","author":"Ong","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.125","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/j.jcf.2021.10.010","article-title":"Management of cystic fibrosis during COVID-19: patient reported outcomes based remote follow-up among CF patients in Denmark \u2013 a feasibility study","volume":"21","author":"Rodkj\u00e6r","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.126","doi-asserted-by":"crossref","first-page":"e14220","DOI":"10.1111\/ijcp.14220","article-title":"Remote support by multidisciplinary teams: a crucial means to cope with the psychological impact of the SARS-CoV-2 pandemic on patients with cystic fibrosis and inflammatory bowel disease in Lombardia","volume":"75","author":"Nobili","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2025102704051883000_11.5.01235-2024.127","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcf.2022.07.002","article-title":"Telehealth and CFTR modulators: accelerating innovative models of cystic fibrosis care","volume":"22","author":"Prickett","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025102704051883000_11.5.01235-2024.128","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210473"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01235-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:07:51Z","timestamp":1761563271000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01235-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":128,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1183\/23120541.01235-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01235-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"type":"electronic","value":"2312-0541"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}